ASPIRE-ing to answer the Triplet question! With Rana McKay and Deepak Kilari
The trial they said would never be done! Huge congrats to the Alliance for Clinical Trials in Oncology who have recently opened the ASPIRE trial, a phase III randomised trial of ADT + apalutamide (doublet), vs ADT + apalutamide + docetaxel chemotherapy (triplet) for men with mHSPC. 1200 men will be…
GU Oncology Highlights From ASCO24
Dr. Neeraj Agarwal and Dr. Rana McKay discuss promising studies in GU cancers featured at the 2024 ASCO Annual Meeting that highlighted improved outcomes in urothelial carcinoma, improved survival in renal cell carcinoma, and the role of ctDNA as a potential biomarker for predicting outcomes.
TR…
THOR, CONTACT-03, and Other Advances in GU Cancers at ASCO23
Drs. Rana McKay and Jonathan Rosenberg highlight key advances in genitourinary cancers featured at the 2023 ASCO Annual Meeting, including the THOR study in mUCC, VESPER in muscle-invasive bladder cancer, CONTACT-03 in mRCC, and TALAPRO-2 in mCRPC.
TRANSCRIPT
Dr. Rana McKay: Hello, and welcome…
ARASEC and Lead-in ADT - China focus
Two interesting papers caught the eye of our GU Cast China team this week; the first is the ARASEC trial which Dr Rana McKay read out in the Practice-Changing Plenary at the AUA Annual Meeting in Washington. This is an interesting comparison of ADT + darolutamide for mHSPC in a prospective US coho…
Ep. 314 Exploring PARP Inhibitor Combinations in Prostate Cancer with Dr. Rana McKay and Dr. Emmanuel Antonarakis
With multiple clinical trials evaluating PARP inhibitor combinations, how do clinicians determine the best approach for advanced prostate cancer? In this episode of BackTable Urology, Dr. Alan Tan is joined by Dr. Rana McKay and Dr. Emmanuel Antonarakis to discuss how evolving evidence, patient sel…
Ep. 71 Exploring PARP Inhibitor Combinations in Prostate Cancer with Dr. Rana McKay and Dr. Emmanuel Antonarakis
With multiple clinical trials evaluating PARP inhibitor combinations, how do clinicians determine the best approach for advanced prostate cancer? In this episode of BackTable Urology, Dr. Alan Tan is joined by Dr. Rana McKay and Dr. Emmanuel Antonarakis to discuss how evolving evidence, patient sel…
ARASEC - Rethinking clinical trial design
Welcome back Rana McKay! Renu was on a flight to Europe this week so Rana jumped into her seat in the GU Cast studio this week to have a chat about the intriguing ARASEC trial which she presented at the AUA Annual Meeting recently. Plus her thoughts on the ARACOG data presented at ASCO last month. …
Cracking the Code in Localized, nmCSPC: Risk, Treatment, and Timing
CME credits: 0.25
Valid until: 30-06-2027
Claim your CME credit at https://reachmd.com/programs/cme/Cracking-the-Code-in-Localized-nmCSPC-Risk-Treatment-and-Timing/56686/
In this podcast, Drs. Rana McKay and Neeraj Agarwal discuss risk stratification in localized and nonmetastatic castrat…
The Future of mCSPC: Molecular Profiling and Biomarker-Directed Therapies
CME credits: 0.25
Valid until: 30-06-2027
Claim your CME credit at https://reachmd.com/programs/cme/The-Future-of-mCSPC-Molecular-Profiling-and-Biomarker-Directed-Therapies/56688/
This podcast explores the evolving role of molecular profiling and biomarker testing in metastatic castration…
Making the Right Moves in Metastatic CSPC: Intensification, Imaging, and Impact
CME credits: 0.25
Valid until: 26-05-2027
Claim your CME credit at https://reachmd.com/programs/cme/Making-the-Right-Moves-in-Metastatic-CSPC-Intensification-Imaging-and-Impact/56687/
Drs. Neeraj Agarwal and Rana McKay discuss treatment intensification strategies in metastatic castration-…
ПОДКАСТ ТЪРСАЧКА
Можете да използвате нашия уебсайт, за да търсите3,829,336подкасти и196,563,750епизоди по хора, места или теми.
I have no special talent. I am only passionately curious, and
I listen to podcasts.
‐ Albert "Llamacorn" Einstein
РЕДАКТИРАНЕ
Благодарим Ви, че помогате да поддържаме базата данни за подкастове актуална.
